Results of an independent oncology review board of pivotal clinical trials of gemcitabine in non-small cell lung cancer.

abstract：:Large (>6 microm) rigid microparticles (MPs) become passively entrapped within the lungs after intravenous (i.v.) injection making them an attractive and highly efficient alternative to inhalation for pulmonary delivery. In this study, PEGylated 6 microm polystyrene MPs with multiple copies of the norvaline (Nva) alph...

journal_title：Anti-cancer drugs

authors： Chao P,Deshmukh M,Kutscher HL,Gao D,Rajan SS,Hu P,Laskin DL,Stein S,Sinko PJ

更新日期：2010-01-01 00:00:00

abstract：:Small molecule tyrosine kinase inhibitors are rapidly being integrated into the management of cancer. This is the first report of sorafenib and sunitinib, both small molecule tyrosine kinase inhibitors of vascular endothelial growth factor and platelet-derived growth factor receptors, triggering radiation recall derma...

journal_title：Anti-cancer drugs

authors： Chung C,Dawson LA,Joshua AM,Brade AM

更新日期：2010-02-01 00:00:00

abstract：:The objective of this study was to evaluate intravesical gemcitabine in high-risk nonmuscle-invasive bladder cancer (NMIBC) refractory to bacillus Calmette-Guérin (BCG). This was a prospective multicentre single-arm trial. Eligible patients were those with high-risk NMIBC refractory to BCG therapy, for which radical c...

journal_title：Anti-cancer drugs

authors： Perdonà S,Di Lorenzo G,Cantiello F,Damiano R,De Sio M,Masala D,Bruni G,Gallo L,Federico P,Quattrone C,Pizzuti M,Autorino R

更新日期：2010-01-01 00:00:00

abstract：:The present study aimed to determine whether actinomycin X2 (AX2) intercepted the mTOR/PTEN/PI3K/Akt signaling pathway to inhibit human prostate cancer cells (PC-3) in vitro. The effects of AX2 on mTOR, PTEN, PI3K, and Akt at the protein level and mRNA were determined by western blotting and real-time reverse transcri...

journal_title：Anti-cancer drugs

authors： Liu J,Xie S,Wu Y,Xu M,Ao C,Wang W,Zeng Q,Hu W,Li M

更新日期：2016-03-01 00:00:00

abstract：:There is growing interest in the discovery of bioactive metabolites from endophytes as an alternative source of therapeutics. Identification of their therapeutic targets is essential in understanding the underlying mechanisms and enhancing the resultant therapeutic effects. As such, bioactive compounds produced by end...

journal_title：Anti-cancer drugs

authors： Hazalin NA,Lim SM,Cole AL,Majeed AB,Ramasamy K

更新日期：2013-09-01 00:00:00

abstract：:CHS 828, a pyridyl cyanoguanidine, is a new drug candidate now in phase I/II trials, that has shown promising anticancer activity in experimental tumor models and primary cultures of cancer cells from patients. In this study the fluorometric microculture cytotoxicity assay was used for evaluation of CHS 828 in primary...

journal_title：Anti-cancer drugs

authors： Frost BM,Lönnerholm G,Nygren P,Larsson R,Lindhagen E

更新日期：2002-08-01 00:00:00

abstract：:Twelve patients received intrapleural instilments of the cytostatic agent mitoxantrone in a total dosage of 30 mg for locoregional palliative therapy of malignant pleural effusion. Effusion could be stopped for a mean period of 3.2 months in 11 patients. ...

journal_title：Anti-cancer drugs

authors： Torsten U,Opri F,Weitzel H

更新日期：1992-02-01 00:00:00

abstract：:Chemotherapy for breast cancer is given on the basis of empirical information from clinical trials, an approach which falls to take into account the known heterogeneity of chemosensitivity between patients. Previous attempts to determine chemosensitivity ex vivo have been disappointing, but in this study results from ...

journal_title：Anti-cancer drugs

authors： Cree IA,Kurbacher CM,Untch M,Sutherland LA,Hunter EM,Subedi AM,James EA,Dewar JA,Preece PE,Andreotti PE,Bruckner HW

更新日期：1996-08-01 00:00:00

abstract：:To investigate the effectiveness of EDL-291, a 6,7-dimethoxy-1-[4-(4-methoxypyridin-3-yl)benzyl]-1,2,3,4-tetrahydroisoquinoline dihydrochloride compound, in inhibiting the survival of glioblastoma in vitro and in vivo. Dose-response curves were generated to determine the EC50 in rat and human glioblastoma cell lines b...

journal_title：Anti-cancer drugs

authors： Wang XD,Freeman NE,Patil R,Patil SA,Mitra S,Orr WE,Abner CW,Yates CR,Miller DD,Geisert EE

更新日期：2012-06-01 00:00:00

abstract：:The aims of this study were to investigate a clinical observation that patients with epithelial ovarian cancer treated with first-line platinum-paclitaxel chemotherapy combination (TP) develop macrocytosis and to explore the possible predictive role of macrocytosis in response rate, progression-free survival (PFS), an...

journal_title：Anti-cancer drugs

authors： Boraska Jelavić T,Boban T,Brčić L,Vrdoljak E

更新日期：2017-09-01 00:00:00

abstract：:Mantle cell lymphoma (MCL) remains incurable for most patients, and proteasome inhibitors like bortezomib induce responses in a minority of patients with relapsed disease. Fenretinide is a retinoid that has shown preclinical activity in B-cell lymphomas. We hypothesized that these agents could yield augmented antitumo...

journal_title：Anti-cancer drugs

authors： Cowan AJ,Frayo SL,Press OW,Palanca-Wessels MC,Pagel JM,Green DJ,Gopal AK

更新日期：2015-10-01 00:00:00

abstract：:Trimetrexate (TMQ), a non-classical folate antagonist, was studied in a randomized controlled trial in patients with advanced colorectal cancer and without prior chemotherapy. Patients were randomly assigned to one of three treatments: TMQ at 200 mg/m2 i.v. q 2 weeks, TMQ at 12 mg/m2 i.v. daily x 5 or 5-fluorouracil (...

journal_title：Anti-cancer drugs

authors： Brown TD,Fleming TR,Goodman PJ,Macdonald JS,Pugh RP,O'Rourke T

更新日期：1995-04-01 00:00:00

abstract：:In this study, we investigated the molecular mechanism of doxorubicin (dxr)-induced cytotoxicity on Jurkat cells - a model cell of human acute lymphoblastic leukemia - under normoxic (20% O2) and hypoxic (5% O2) conditions. Using in-cell western analysis, immunofluorescence, flow cytometry analysis, and biochemical in...

journal_title：Anti-cancer drugs

authors： Mendivil-Perez M,Velez-Pardo C,Jimenez-Del-Rio M

更新日期：2015-07-01 00:00:00

abstract：:C-reactive protein (CRP) is an independent prognostic factor for renal cell carcinoma (RCC). The aim of the present study was to investigate the overall prognostic impact of CRP in patients with metastatic RCC treated with sorafenib. Between April 2008 and December 2014, 40 consecutive patients with metastatic RCC wer...

journal_title：Anti-cancer drugs

authors： Fujita T,Nishi M,Tabata K,Matsumoto K,Yoshida K,Iwamura M

更新日期：2016-11-01 00:00:00

abstract：:The use of viability assays to assess the effect of antineoplastic agents on cell lines and tumor cells is an important investigative tool and may have clinical relevance. Such assays require very small quantities of drugs and it is the practice of many laboratories to freeze aliquots of drugs for use in these assays ...

journal_title：Anti-cancer drugs

authors： Hunter EM,Sutherland LA,Cree IA,Subedi AM,Hartmann D,Linder D,Andreotti PE

更新日期：1994-04-01 00:00:00

abstract：:Creatine kinase (CK), a key enzyme of cellular energetics, has been implicated in tumorigenesis. Cyclocreatine (CCr), which forms a stable phosphagen with a reduced rate of ATP regeneration through CK, inhibits the growth of many solid tumors. We report that CCr induces the formation of unusually stable microtubules t...

journal_title：Anti-cancer drugs

authors： Martin KJ,Vassallo CD,Teicher BA,Kaddurah-Daouk R

更新日期：1995-06-01 00:00:00

abstract：:Previously, we synthesized a series of hydrazide class of compounds and examined their cytotoxicity in a number of cancer cell lines. Among these analogues, SC144 exhibited potent cytotoxicity against a panel of drug-sensitive and drug-resistant cancer cell lines. To further explore its therapeutic potentials in the c...

journal_title：Anti-cancer drugs

authors： Oshima T,Cao X,Grande F,Yamada R,Garofalo A,Louie S,Neamati N

更新日期：2009-06-01 00:00:00

abstract：:Lymphocytes regenerated after treatment with a high dose of cyclophosphamide (CY) were characterized in nude mice. Ten days after a single injection of 200 mg/kg CY into nude mice, regenerated spleen cells suppressed in vitro primary and second antibody production against sheep red blood cells. The CY-treated spleen c...

journal_title：Anti-cancer drugs

authors： Shimizu M,Sabolovic D,Ozawa H,Iwaguchi T

更新日期：1992-08-01 00:00:00

abstract：:2-(4-Amino-3-methylphenyl)-5-fluoro-benzothiazole (5F 203) potently inhibits MCF-7 breast cancer cell growth in part by activating the aryl hydrocarbon receptor (AhR) signaling pathway. Ligands for the AhR (i.e. dioxin) have also been shown to modulate the NF-kappaB signaling cascade, affecting physiological processes...

journal_title：Anti-cancer drugs

authors： Brantley E,Patel V,Stinson SF,Trapani V,Hose CD,Ciolino HP,Yeh GC,Gutkind JS,Sausville EA,Loaiza-Pérez AI

更新日期：2005-02-01 00:00:00

abstract：:Tafluposide (F 11782), a novel epipodophylloid with a unique mechanism of interaction with both topoisomerase I and II, has shown outstanding antitumor activity in vivo against a panel of experimental human tumor xenografts. The aim of this study was to evaluate its cytotoxicity against fresh tumor cells taken from pa...

journal_title：Anti-cancer drugs

authors： Sargent JM,Elgie AW,Williamson CJ,Hill BT

更新日期：2003-07-01 00:00:00

abstract：:Metformin, an oral antidiabetic agent, has been reported to potentiate chemotherapeutic-induced cytotoxicity. In this study, we investigated the effects and molecular mechanisms of metformin in sensitizing tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human bladder cancer cells. ...

journal_title：Anti-cancer drugs

authors： Zhang T,Wang X,He D,Jin X,Guo P

更新日期：2014-09-01 00:00:00

abstract：:The main aim of this study is to assess the safety and antitumor efficacy of a palladium(II) (Pd)-saccharinate complex with terpyridine. To characterize the Pd(II) complex in vitro, its cytotoxicity was evaluated using a water-soluble tetrazolium salt cell viability assay and the mechanism of cell death was assessed b...

journal_title：Anti-cancer drugs

authors： Cetin Y,Adiguzel Z,Polat HU,Akkoc T,Tas A,Cevatemre B,Celik G,Carikci B,Yilmaz VT,Ulukaya E,Acilan C

更新日期：2017-09-01 00:00:00

abstract：:Isoquercitrin isolated from the aerial parts of Hyptis fasciculata was evaluated according to its capacity to interfere with glioblastoma (Gbm) cell growth. Gbm cells were incubated with isoquercitrin, quercetin, or rutin at concentrations of 25, 50, and 100 mumol/l for 24, 48, and 72 h. Quercetin and rutin affected G...

journal_title：Anti-cancer drugs

authors： Amado NG,Cerqueira DM,Menezes FS,da Silva JF,Neto VM,Abreu JG

更新日期：2009-08-01 00:00:00

abstract：:Adrenocortical tumor (ACT) is a malignancy with a low incidence rate and the current therapy for advanced disease has a limited impact on overall patient survival. A previous study from our group suggested that elevated expression of aurora-A and aurora-B is associated with poor outcome in childhood ACT. Similar resul...

journal_title：Anti-cancer drugs

authors： Borges KS,Andrade AF,Silveira VS,Marco Antonio DS,Vasconcelos EJR,Antonini SRR,Tone LG,Scrideli CA

更新日期：2017-07-01 00:00:00

abstract：:We performed a phase II, Southwest Oncology Group (SWOG) clinical trial of recombinant human interleukin-4 (rhuIL-4) in patients with previously treated non-Hodgkin's lymphoma (NHL). We studied 18 eligible patients with low-grade and 21 patients with intermediate- or high-grade NHL. All patients had received prior che...

journal_title：Anti-cancer drugs

authors： Taylor CW,LeBlanc M,Fisher RI,Moore DF Sr,Roach RW,Elias L,Miller TP

更新日期：2000-10-01 00:00:00

abstract：:The aim of the present study was to investigate the gene expression of biomarkers associated with the sensitivity to fluoropyrimidine and taxanes in recurrent/advanced breast cancer patients treated with first-line capecitabine chemotherapy. We evaluated the clinicopathological/prognostic significance of thymidylate s...

journal_title：Anti-cancer drugs

authors： Zhao HY,Huang H,Hu ZH,Huang Y,Lin SX,Tian Y,Lin TY

更新日期：2012-06-01 00:00:00

abstract：:The antitumor effects of a polyamine biosynthetic pathway inhibitor methylglyoxal bis(cyclopentylamidinohydrazone) (MGBCP) on the human hepatocellular carcinoma SK-HEP-1 cell line have been investigated. The growth of these cultured hepatocellular carcinoma cells was inhibited by MGBCP in a dose-dependent manner. Sper...

journal_title：Anti-cancer drugs

authors： Hashimoto Y,Hibasami H,Tamaki S,Kamei A,Ikoma J,Kaito M,Imoto I,Watanabe S,Nakashima K,Adachi Y

更新日期：1999-03-01 00:00:00

abstract：:Taxotere (RP 56976, NSC 628503) is a new semisynthetic analog of taxol (NSC 125973) with promising antitumor activity in a variety of preclinical screening systems. Clinical responses after treatment with taxol have been observed in ovarian cancer, breast, lung cancer and melanoma. Both agents act through induction of...

journal_title：Anti-cancer drugs

authors： Hanauske AR,Degen D,Hilsenbeck SG,Bissery MC,Von Hoff DD

更新日期：1992-04-01 00:00:00

abstract：:We evaluated the activity and toxicity of two sequences of taxol combined with vinorelbine in disseminated malignant melanoma, metastatic beyond regional lymph nodes. Fifteen previously untreated patients, nine males and six females (median age 56 years), were enlisted between May 1994 and February 1995. Eight patient...

journal_title：Anti-cancer drugs

authors： Retsas S,Mohith A,Mackenzie H

更新日期：1996-02-01 00:00:00

abstract：:Mitomycin C (MMC) in combination with infusional 5-fluorouracil (5-FU) is a well-tolerated active combination therapy for advanced gastric cancer. Pegylated liposomal doxorubicin (Caelyx) has been combined with this regimen in a phase I study exhibiting promising activity in patients with upper gastrointestinal tumors...

journal_title：Anti-cancer drugs

authors： Gnad-Vogt SU,Hofheinz RD,Saussele S,Kreil S,Willer A,Willeke F,Pilz L,Hehlmann R,Hochhaus A

更新日期：2005-04-01 00:00:00